의약품 부형제 시장 : 제품별, 기능별, 제형별, 기능 용도별 - 세계 예측(-2031년)

The global pharmaceutical excipients market is projected to reach USD 15.99 billion by 2031 from USD 11.95 billion in 2026, at a CAGR of 6.0% during the forecast period. The expansion of the pharmaceutical excipients market has been driven primarily by surging demand for pharmaceutical products and generic medicines, and R&D investments in novel excipient development.

Additionally, partnerships & collaborations with pharmaceutical companies and increased emphasis on patient-centric formulations will provide lucrative market growth opportunities. However, regulatory stringency and steep development costs are predicted to restrict the market.

In 2025, the fillers & diluents functionality held the highest share in the pharmaceutical excipients market.

The pharmaceutical excipients market, segmented by functionality, includes binders, suspending and viscosity agents, fillers and diluents, flavoring agents and sweeteners, colorants, coating agents, lubricants and glidants, preservatives, disintegrants, emulsifying agents, and other specialized roles. Among these, fillers and diluents play a critical role, especially in the production of solid oral dosage forms like tablets and capsules. Their importance continues to grow with the rising demand for oral medications, which remain the most preferred route due to ease of administration and patient compliance. Fillers and diluents provide bulk to formulations containing small amounts of active pharmaceutical ingredients and help ensure accurate dosage and improved content uniformity. From a manufacturing perspective, they contribute significantly to formulation stability, ease of processing, and scalability in mass production. They simplify processes such as blending, tableting, and encapsulation while enhancing the mechanical strength of tablets. For patients, these excipients improve mouthfeel, taste, and handling, which are crucial factors for pediatric and geriatric populations. As drug formulations become more complex, the demand for high-performance, multifunctional fillers and diluents that support controlled release and bioavailability enhancement is also rising, presenting significant growth opportunities in this excipient category.

The oral formulations segment accounted for the highest share of the pharmaceutical excipients market in 2025.

The pharmaceutical excipients market is categorized based on formulation types into oral formulations, topical formulations, parenteral formulations, and other formulations. Among these, the oral formulations segment held the largest market share in 2025, reflecting its dominance as the most widely used and traditional drug delivery method. The convenience, cost-effectiveness, and high patient compliance associated with oral administration make it a preferred choice for patients and healthcare providers. This segment continues to expand due to the rising demand for tablets, capsules, and other solid oral dosage forms. Furthermore, the rapid growth of the biopharmaceutical and generics industries is playing a pivotal role in driving demand for high-quality excipients that enhance drug stability, solubility, and bioavailability in oral products. The increasing prevalence of chronic conditions requiring long-term medication and the trend toward self-administration of drugs also contribute to the growth of this segment. As a result, pharmaceutical companies are investing in innovative oral drug formulations, boosting the need for advanced excipients tailored to these needs.

Asia Pacific is expected to grow at the highest CAGR in the global pharmaceutical excipients market from 2026 to 2031.

The pharmaceutical excipients market in the Asia Pacific region is expected to grow robustly and register the highest CAGR among all regions during the forecast period. Several interrelated factors are driving this expansion. One of the key advantages is the region's cost-effective manufacturing capabilities, which make it an attractive hub for pharmaceutical production and outsourcing. Countries like India, China, and South Korea offer abundant raw material availability, skilled labor, and favorable government policies that support pharmaceutical R&D and export-oriented manufacturing. Additionally, the Asia Pacific region has relatively lenient regulatory frameworks compared to Western markets, which accelerates product development and time-to-market. The rapid rise in per capita income, growing awareness of health and wellness, and increased healthcare spending are further fueling demand for generic drugs and, by extension, pharmaceutical excipients. Moreover, a surge in lifestyle-related chronic diseases and expanding geriatric populations have led to greater demand for innovative drug formulations, including oral solids and topical applications. These trends create significant opportunities for local and global excipient manufacturers to expand operations, invest in infrastructure, and form strategic partnerships to meet the growing regional demand.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side-70% and Demand Side-30%
• By Designation: Managers-45%, CXOs & Directors-30%, and Executives-25%
• By Region: North America-40%, Europe-25%, the Asia Pacific-20%, Latin America-10%, and the Middle East & Africa-5%

List of Key Companies Profiled in the Report

Key players in the pharmaceutical excipients market include Roquette Freres (France), ADM (US), , Evonik Industries AG (Germany), BASF SE (Germany), Ashland Inc. (US), Kerry Group plc (Ireland), MERCK KGaA (Germany), Associated British Foods plc (UK), Wacker Chemie AG (Germany), Air Liquide (France), DOW (US), Berkshire Hathaway Inc. (US), Colorcon (US), DFE PHARMA (Germany), Actylis (US), Croda International Plc (UK), Gattefosse (France), JRS Pharma (Germany), and Shin-Etsu Chemical Co., Ltd. (Japan).

Research Coverage

This research report categorizes the pharmaceutical excipients market by Product [Organic (Oleochemicals, Carbohydrates, Petrochemicals, Proteins, and Other Organic Chemicals), Inorganic (Calcium Phosphate, Metal Oxides, Halites, Calcium Carbonate, Calcium Sulfate, Other Inorganic Chemicals), Other chemicals], by Functionality (Fillers & Diluents, Suspending & Viscosity Agents, Coating Agents, Binders, Flavoring Agents & Sweeteners, Disintegrants, Colorants, Lubricants & Glidants, Preservatives, Emulsifying Agents, and Other Functionalities), by formulation (Oral (Tablets, Capsules, Liquid Formulations and other oral formulations), Topical Formulations, Parenteral Formulations, and Other Formulations), by Functionality Application (Stabilizers, Taste Masking, Modified Release, Solubility & Bioavailability Enhancement and Other Functionality Applications), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the pharmaceutical excipients market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. The report also covers new approvals/launches, collaborations, acquisitions, and recent developments associated with the pharmaceutical excipients market.

Reasons to Buy this Report

The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical excipients market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and devise suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Surging demand for generic medications and pharmaceutical formulations, Increased R&D investments to develop novel excipients, A growing focus on patient-centric drug formulations, Strategic collaborations and partnerships with pharmaceutical firms), restraints (Strict and complex regulatory frameworks, High costs associated with excipient development and manufacturing), opportunities (Increasing interest in functional and multifunctional excipients, Technological advancements, particularly in nanotechnology, Expansion into emerging economies across Asia Pacific and Latin America), and Challenges (Ongoing concerns about excipient safety and quality standards, Limited availability and fluctuating costs of key raw materials).
• Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the Pharmaceutical Excipients market.
• Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the pharmaceutical excipients market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the pharmaceutical excipients market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS CONSIDERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET SNAPSHOT
• 3.2 NORTH AMERICA: PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION AND COUNTRY, 2025
• 3.3 PHARMACEUTICAL EXCIPIENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Surging demand for generic medications and pharmaceutical formulations
    • 4.2.1.2 Increased R&D investments to develop novel excipients
    • 4.2.1.3 Growing focus on patient-centric drug formulations
    • 4.2.1.4 Collaborations and partnerships among pharmaceutical firms
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Strict and complex regulatory frameworks
    • 4.2.2.2 High cost of excipient development and manufacturing
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Increasing interest in functional and multifunctional excipients
    • 4.2.3.2 Technological advancements in nanotechnology
    • 4.2.3.3 Market opportunities in emerging economies
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Ongoing concerns about excipient safety and quality standards
    • 4.2.4.2 Limited availability and fluctuating costs of key raw materials
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 BARGAINING POWER OF SUPPLIERS
  • 5.1.2 BARGAINING POWER OF BUYERS
  • 5.1.3 THREAT OF NEW ENTRANTS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET
  • 5.2.4 TRENDS IN HEALTHCARE EXPENDITURE
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 SUPPLY CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 PRICING ANALYSIS
  • 5.6.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2025
  • 5.6.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2025
• 5.7 TRADE ANALYSIS
  • 5.7.1 TRADE DATA (HS CODE 290545)
    • 5.7.1.1 Import data for HS code 290545
    • 5.7.1.2 Export data for HS code 290545
  • 5.7.2 TRADE DATA (HS CODE 350510)
    • 5.7.2.1 Import data for HS code 350510
    • 5.7.2.2 Export data for HS code 350510
  • 5.7.3 TRADE DATA (HS CODE 290532)
    • 5.7.3.1 Import data for HS code 290532
    • 5.7.3.2 Export data for HS code 290532
  • 5.7.4 TRADE DATA (HS CODE 283650)
    • 5.7.4.1 Import data for HS code 283650
    • 5.7.4.2 Export data for HS code 283650
  • 5.7.5 TRADE DATA (HS CODE 250100)
    • 5.7.5.1 Import data for HS code 250100
    • 5.7.5.2 Export data for HS code 250100
  • 5.7.6 TRADE DATA (HS CODE 290543)
    • 5.7.6.1 Import data for HS code 290543
    • 5.7.6.2 Export data for HS code 290543
  • 5.7.7 TRADE DATA (HS CODE 3912)
    • 5.7.7.1 Import data for HS code 3912
    • 5.7.7.2 Export data for HS code 3912
• 5.8 KEY CONFERENCES & EVENTS
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.10 INVESTMENT/FUNDING ACTIVITY
• 5.11 CASE STUDY ANALYSIS
  • 5.11.1 CASE STUDY 1: MOISTURE PROTECTION FOR MOISTURE-SENSITIVE TABLETS
  • 5.11.2 CASE STUDY 2: STABILIZATION OF MONOCLONAL ANTIBODY FORMULATIONS
• 5.12 IMPACT OF 2025 US TARIFFS-PHARMACEUTICAL EXCIPIENTS MARKET
  • 5.12.1 INTRODUCTION
  • 5.12.2 KEY TARIFF RATES
  • 5.12.3 PRICE IMPACT ANALYSIS
  • 5.12.4 COMPARATIVE PRICING ON KEY EXCIPIENT PRE AND POST US 2025 TARIFFS
  • 5.12.5 IMPACT ON COUNTRIES/REGIONS
    • 5.12.5.1 North America
      • 5.12.5.1.1 US
    • 5.12.5.2 Europe
    • 5.12.5.3 Asia Pacific
  • 5.12.6 IMPACT ON END-USE INDUSTRIES

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY TECHNOLOGIES
    • 6.1.1.1 Co-processed excipient technology
    • 6.1.1.2 Nanotechnology-based excipients
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 3D printing/additive manufacturing
    • 6.1.2.2 Process Analytical Technology (PAT)
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Artificial intelligence in formulation design
    • 6.1.3.2 Green chemistry/sustainability tech
• 6.2 TECHNOLOGY/PRODUCT ROADMAP
• 6.3 PATENT ANALYSIS
  • 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR PHARMACEUTICAL EXCIPIENTS PATENTS, 2015-2025
• 6.4 FUTURE APPLICATIONS
• 6.5 IMPACT OF AI/GEN AI ON PHARMACEUTICAL EXCIPIENTS MARKET
  • 6.5.1 INTRODUCTION
  • 6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN PHARMACEUTICAL EXCIPIENTS MARKET
  • 6.5.3 AI USE CASES
  • 6.5.4 KEY COMPANIES IMPLEMENTING AI
  • 6.5.5 FUTURE OF GENERATIVE AI IN PHARMACEUTICAL EXCIPIENT ECOSYSTEM
• 6.6 SUCCESS STORIES AND REAL-WORLD APPLICATIONS

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

• 7.1 REGULATORY LANDSCAPE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 REGULATORY FRAMEWORK
    • 7.1.2.1 US
    • 7.1.2.2 Europe
    • 7.1.2.3 China
    • 7.1.2.4 India
    • 7.1.2.5 Brazil
  • 7.1.3 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY INITIATIVES
• 7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 PHARMACEUTICAL EXCIPIENTS MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 ORGANIC CHEMICALS
  • 9.2.1 OLEOCHEMICALS
    • 9.2.1.1 Fatty alcohols
      • 9.2.1.1.1 Wide usage of fatty alcohols as nonionic surfactants due to their amphipathic nature to drive market growth
    • 9.2.1.2 Mineral stearates
    • 9.2.1.3 Wide use of magnesium stearates as excipients in nutraceutical and pharmaceutical formulations to drive market growth
    • 9.2.1.4 Glycerin
      • 9.2.1.4.1 Extensive applications of glycerin to drive market growth
    • 9.2.1.5 Other oleochemicals
  • 9.2.2 CARBOHYDRATES
    • 9.2.2.1 Sugars
    • 9.2.2.2 Actual sugars
    • 9.2.2.3 Lactose
      • 9.2.2.3.1 Superior compressibility and widespread use in solid oral dosage forms to propel segment growth
    • 9.2.2.4 Sucrose
      • 9.2.2.4.1 Increasing usage of sucrose in pediatric, oral liquid, and lyophilized biologic formulations to drive growth
    • 9.2.2.5 Dextrose (D-Glucose)
      • 9.2.2.5.1 Growing use of dextrose in injectable and rehydration therapies to support growth
    • 9.2.2.6 Sugar alcohols
    • 9.2.2.7 Sorbitol
      • 9.2.2.7.1 Rising demand for sorbitol as stabilizer and sweetening agent in liquid and chewable formulations to fuel market
    • 9.2.2.8 Mannitol
      • 9.2.2.8.1 Expanding use of mannitol in solid dosage and lyophilized biologics due to its non-hygroscopic and stabilizing properties to aid growth
    • 9.2.2.9 Other sugar alcohols
    • 9.2.2.10 Artificial sweeteners
      • 9.2.2.10.1 Wide usage of aspartame as artificial sweetener to drive market growth
    • 9.2.2.11 Cellulose
    • 9.2.2.12 Microcrystalline cellulose
      • 9.2.2.12.1 Most widely used excipient in direct compression method for tablets to boost market
    • 9.2.2.13 Cellulose ethers
      • 9.2.2.13.1 Highly effective even at lower concentrations to boost demand for cellulose ethers
    • 9.2.2.14 CMC & croscarmellose sodium
      • 9.2.2.14.1 Multiple advantages of CMC and croscarmellose sodium to drive market growth
    • 9.2.2.15 Cellulose esters
      • 9.2.2.15.1 Delivery of drugs in cellular membranes and intracellular matrix to support market growth
    • 9.2.2.16 Starch
    • 9.2.2.17 Modified starch
      • 9.2.2.17.1 Growing use in sustained-release tablets due to its cold-water swelling and gel barrier formation capabilities to drive market growth
    • 9.2.2.18 Dried starch
      • 9.2.2.18.1 Strong binding and coating agent to boost adoption
    • 9.2.2.19 Converted starch
      • 9.2.2.19.1 Growing use of converted starch as molecular encapsulation agent to support market
  • 9.2.3 PETROCHEMICALS
    • 9.2.3.1 Glycols
      • 9.2.3.1.1 Availability of highly purified polyethylene glycol to enhance market demand
    • 9.2.3.2 Polyethylene glycol (PEG)
      • 9.2.3.2.1 Increasing adoption of PEG as versatile excipient in topical, oral, and parenteral formulations to boost market
    • 9.2.3.3 Propylene glycol (PG)
      • 9.2.3.3.1 Rising use in oral and injectable formulations for solvent, humectant, and preservative-enhancing functions to boost demand
    • 9.2.3.4 Povidones
      • 9.2.3.4.1 Rising demand for fast-dissolving tablets to propel growth
    • 9.2.3.5 Mineral hydrocarbons
      • 9.2.3.5.1 Growing preference for topical formulations in pain management to support demand for mineral hydrocarbons
    • 9.2.3.6 Petrolatum
      • 9.2.3.6.1 Occlusive and emollient properties of petrolatum to drive adoption
    • 9.2.3.7 Mineral waxes
      • 9.2.3.7.1 Utilization of mineral waxes in solid and semi-solid dosage forms for structure enhancement and controlled drug release to boost market
    • 9.2.3.8 Mineral oils
      • 9.2.3.8.1 Extensive use of mineral oils as solvents and emollients in topical, oral, and parenteral pharmaceutical applications to drive growth
    • 9.2.3.9 Acrylic polymers
      • 9.2.3.9.1 Wide use of acrylic polymers in controlled-release drug formulations to drive market growth
    • 9.2.3.10 Other petrochemical excipients
  • 9.2.4 PROTEINS
    • 9.2.4.1 Growing applications of proteins as carriers for microparticles and nanoparticles to drive market growth
  • 9.2.5 OTHER ORGANIC CHEMICALS
• 9.3 INORGANIC CHEMICALS
  • 9.3.1 CALCIUM PHOSPHATE
    • 9.3.1.1 Chemical purity and low incompatibility with drugs to aid their high usage in pharmaceutical industry
  • 9.3.2 METAL OXIDES
    • 9.3.2.1 Availability of silicon oxides in hydrophobic, hydrophilic, and granulated forms to aid market growth
  • 9.3.3 HALITES
    • 9.3.3.1 Increased utilization of halites in vaccines and controlled-release formulations to drive market demand
  • 9.3.4 CALCIUM CARBONATE
    • 9.3.4.1 Properties such as short disintegration time and excellent mechanical strength to drive market
  • 9.3.5 CALCIUM SULFATE
    • 9.3.5.1 Advantages such as cost-effective, quality-enhancing diluent for solid dosage forms to boost demand
  • 9.3.6 OTHER INORGANIC CHEMICALS
• 9.4 OTHER CHEMICALS

10 PHARMACEUTICAL EXCIPIENTS MARKET, BY FORMULATION

• 10.1 INTRODUCTION
• 10.2 ORAL FORMULATIONS
  • 10.2.1 TABLETS
    • 10.2.1.1 Wide usage of tablets to support market growth
  • 10.2.2 CAPSULES
    • 10.2.2.1 Hard-gelatin capsules
      • 10.2.2.1.1 Ease of manufacturing and versatility to drive growth of hard-gelatin capsules market
    • 10.2.2.2 Soft-gelatin capsules
      • 10.2.2.2.1 Stability concerns with highly water-soluble compounds and compounds susceptible to hydrolysis to restrict market growth
  • 10.2.3 LIQUID FORMULATIONS
    • 10.2.3.1 Liquid formulations require no dissolution time and boast faster absorption from stomach than tablets-key factors driving growth
  • 10.2.4 OTHER ORAL FORMULATIONS
• 10.3 TOPICAL FORMULATIONS
  • 10.3.1 ADVANTAGES OF TOPICAL DRUG DELIVERY TO DRIVE DEMAND FOR EXCIPIENTS IN THIS SEGMENT
• 10.4 PARENTERAL FORMULATIONS
  • 10.4.1 EMERGENCE OF NEW BIOLOGICAL MOLECULES TO INCREASE DEMAND FOR EXCIPIENTS
• 10.5 OTHER FORMULATIONS

11 PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY

• 11.1 INTRODUCTION
• 11.2 FILLERS & DILUENTS
  • 11.2.1 IMPROVED COHESION, DIRECT COMPRESSION, AND FLOW TO FINAL DOSE IN TABLETS TO BOOST MARKET DEMAND
• 11.3 SUSPENDING & VISCOSITY AGENTS
  • 11.3.1 ADVANTAGES SUCH AS DRUG STABILITY AND TASTE MASKING TO BOOST MARKET GROWTH
• 11.4 COATING AGENTS
  • 11.4.1 INCREASING USE OF SUSTAINED-RELEASE FORMULATIONS IN PHARMA INDUSTRY TO DRIVE MARKET GROWTH
• 11.5 BINDERS
  • 11.5.1 FLUIDITY AND COMPRESSIBILITY ESSENTIAL FOR TABLET MANUFACTURING ASSOCIATED WITH BINDERS TO SUPPORT MARKET
• 11.6 FLAVORING AGENTS & SWEETENERS
  • 11.6.1 ABILITY TO IMPROVE PALATABILITY OF DRUGS TO DRIVE DEMAND
• 11.7 DISINTEGRANTS
  • 11.7.1 ABILITY TO CAUSE RAPID BREAK-UP OF SOLID DOSAGE FORMS TO BOOST ADOPTION
• 11.8 COLORANTS
  • 11.8.1 GROWING USE IN HARD AND SOFT GELATIN CAPSULES, TABLETS, ORAL LIQUIDS, AND TOPICAL CREAMS TO FUEL GROWTH
• 11.9 LUBRICANTS & GLIDANTS
  • 11.9.1 ABILITY TO IMPROVE FLOW PROPERTIES OF FORMULATIONS BY REDUCING INTERPARTICLE FRICTION AND COHESION TO DRIVE GROWTH
• 11.10 PRESERVATIVES
  • 11.10.1 GROWING USE OF BENZYL ALCOHOL IN PHARMACEUTICAL AND NUTRACEUTICAL INDUSTRIES TO SUPPORT GROWTH
• 11.11 EMULSIFYING AGENTS
  • 11.11.1 USE OF SOLUBILITY ENHANCEMENT EXCIPIENTS IN LIQUID DRUG FORMULATIONS TO INCREASE API BIOAVAILABILITY TO DRIVE DEMAND
• 11.12 OTHER FUNCTIONALITIES

12 PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY APPLICATION

• 12.1 INTRODUCTION
• 12.2 STABILIZERS
  • 12.2.1 ADVANTAGES SUCH AS IMPROVED DRUG SHELF LIFE AND FEWER MANUFACTURING DEFECTS TO BOOST DEMAND
• 12.3 TASTE MASKING
  • 12.3.1 BENEFITS SUCH AS GREATER PATIENT COMPLIANCE AND ADHERENCE TO MEDICATION REGIMENS TO FUEL MARKET
• 12.4 MODIFIED-RELEASE
  • 12.4.1 INCREASING USE OF MODIFIED-RELEASE FORMULATIONS IN PHARMA INDUSTRY TO DRIVE MARKET GROWTH
• 12.5 SOLUBILITY & BIOAVAILABILITY ENHANCEMENT
  • 12.5.1 ESSENTIAL NATURE OF SOLUBILITY AND BIOAVAILABILITY FORMULATIONS FOR EFFECTIVE DRUG DELIVERY TO BOOST ADOPTION
• 12.6 OTHER FUNCTIONALITY APPLICATIONS

13 PHARMACEUTICAL EXCIPIENTS MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 EUROPE
  • 13.2.1 GERMANY
    • 13.2.1.1 Germany accounted for largest share of European pharmaceutical excipients market in 2025
  • 13.2.2 UK
    • 13.2.2.1 Growing adoption of generics and development of novel multi-functional, co-processed excipients to drive market growth
  • 13.2.3 FRANCE
    • 13.2.3.1 Large geriatric population in country to support market growth
  • 13.2.4 ITALY
    • 13.2.4.1 Budgetary constraints and restricted healthcare spending to impede growth of Italian market
  • 13.2.5 SPAIN
    • 13.2.5.1 High consumption of biologics to support market growth
  • 13.2.6 REST OF EUROPE
• 13.3 NORTH AMERICA
  • 13.3.1 US
    • 13.3.1.1 US to dominate North American market
  • 13.3.2 CANADA
    • 13.3.2.1 Strong growth of emerging markets and slowdown in new product approvals to hamper market growth in Canada
• 13.4 ASIA PACIFIC
  • 13.4.1 CHINA
    • 13.4.1.1 Emphasis on generics and off-patent drugs to drive market in China
  • 13.4.2 JAPAN
    • 13.4.2.1 Rapid growth of Japan's geriatric population to greatly drive demand for pharmaceuticals
  • 13.4.3 INDIA
    • 13.4.3.1 Leading producer of generics to drive growth in India market
  • 13.4.4 SOUTH KOREA
    • 13.4.4.1 Presence of leading contract research and development organizations to propel market growth
  • 13.4.5 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 BRAZIL
    • 13.5.1.1 Emerging opportunities for excipient manufacturers in Brazil to boost growth
  • 13.5.2 MEXICO
    • 13.5.2.1 Growing demand for affordable therapies and contract manufacturing to support growth
  • 13.5.3 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST
  • 13.6.1 GCC COUNTRIES
    • 13.6.1.1 healthcare infrastructure expansion and localization of drug manufacturing to drive excipients market in GCC Countries
  • 13.6.2 REST OF MIDDLE EAST
• 13.7 AFRICA
  • 13.7.1 UNSATURATED MARKETS IN THE REGION HAVE DRAWN THE ATTENTION OF GLOBAL PLAYERS

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PHARMACEUTICAL EXCIPIENTS MARKET, 2023-2026
• 14.3 REVENUE ANALYSIS, 2023-2025
• 14.4 MARKET SHARE ANALYSIS, 2025
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2025
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Region footprint
    • 14.5.5.3 Product footprint
    • 14.5.5.4 Functionality footprint
    • 14.5.5.5 Functionality application footprint
• 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 14.6.5.1 Detailed list of key startups/SMEs
    • 14.6.5.2 Competitive benchmarking of key startups/SMEs
• 14.7 COMPANY VALUATION AND FINANCIAL METRICS
• 14.8 BRAND/PRODUCT COMPARISON
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT APPROVALS & LAUNCHES
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 ROQUETTE FRERES
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product launches
      • 15.1.1.3.2 Deals
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Key strengths
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses and competitive threats
  • 15.1.2 ARCHER-DANIELS-MIDLAND COMPANY
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Deals
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Key strengths
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses and competitive threats
  • 15.1.3 BASF SE
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Deals
      • 15.1.3.3.2 Expansions
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Key strengths
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses and competitive threats
  • 15.1.4 EVONIK INDUSTRIES AG
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Expansions
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Key strengths
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses and competitive threats
  • 15.1.5 ASHLAND INC.
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Product launches and approvals
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Key strengths
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses and competitive threats
  • 15.1.6 KERRY GROUP PLC
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Deals
  • 15.1.7 MERCK KGAA
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Deals
  • 15.1.8 ASSOCIATED BRITISH FOODS PLC
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Deals
  • 15.1.9 WACKER CHEMIE AG
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products offered
  • 15.1.10 AIR LIQUIDE S.A.
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Product launches
  • 15.1.11 DOW INC.
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products offered
  • 15.1.12 BERKSHIRE HATHAWAY INC. (LUBRIZOL CORPORATION)
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products offered
  • 15.1.13 COLORCON, INC.
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products offered
    • 15.1.13.3 Recent developments
      • 15.1.13.3.1 Product launches
      • 15.1.13.3.2 Deals
      • 15.1.13.3.3 Expansions
  • 15.1.14 DFE PHARMA GMBH & CO. KG
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products offered
  • 15.1.15 ACTYLIS
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products offered
    • 15.1.15.3 Recent developments
      • 15.1.15.3.1 Deals
  • 15.1.16 CRODA INTERNATIONAL PLC
    • 15.1.16.1 Business overview
    • 15.1.16.2 Products offered
    • 15.1.16.3 Recent developments
      • 15.1.16.3.1 Deals
      • 15.1.16.3.2 Expansions
  • 15.1.17 GATTEFOSSE SAS
    • 15.1.17.1 Business overview
    • 15.1.17.2 Products offered
  • 15.1.18 J. RETTENMAIER & SOHNE GMBH + CO KG
    • 15.1.18.1 Business overview
    • 15.1.18.2 Products offered
  • 15.1.19 SHIN-ETSU CHEMICAL CO., LTD.
    • 15.1.19.1 Business overview
    • 15.1.19.2 Products offered
    • 15.1.19.3 Recent developments
      • 15.1.19.3.1 Deals
      • 15.1.19.3.2 Expansions
• 15.2 OTHER PLAYERS
  • 15.2.1 INNOPHOS HOLDINGS, INC.
  • 15.2.2 MEGGLE GMBH & CO. KG
  • 15.2.3 FUJI CHEMICAL INDUSTRIES CO., LTD.
  • 15.2.4 COREL PHARMA CHEM PVT. LTD.
  • 15.2.5 BIOGRUND GMBH
  • 15.2.6 NITIKA PHARMACEUTICAL SPECIALTIES PVT. LTD.
  • 15.2.7 R.T. VANDERBILT HOLDING COMPANY, INC.
  • 15.2.8 BENEO GMBH
  • 15.2.9 SIGACHI INDUSTRIES LIMITED
  • 15.2.10 JH NANHANG LIFE SCIENCES CO., LTD.

16 RESEARCH METHODOLOGY

• 16.1 RESEARCH DATA
  • 16.1.1 SECONDARY DATA
    • 16.1.1.1 Objectives of secondary research
    • 16.1.1.2 Key data from secondary sources
  • 16.1.2 PRIMARY DATA
    • 16.1.2.1 Breakdown of primaries (supply- and demand-side participants)
    • 16.1.2.2 Key objective of primary research
• 16.2 MARKET ESTIMATION
  • 16.2.1 GLOBAL MARKET ESTIMATION
    • 16.2.1.1 Company revenue analysis (bottom-up approach)
    • 16.2.1.2 Revenue share analysis of Roquette Freres
    • 16.2.1.3 MnM repository analysis
    • 16.2.1.4 Primary interviews
  • 16.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 16.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
• 16.3 MARKET GROWTH RATE PROJECTIONS
• 16.4 DATA TRIANGULATION
• 16.5 STUDY ASSUMPTIONS
• 16.6 RESEARCH LIMITATIONS
• 16.7 RISK ANALYSIS

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS